Materials and Methods for preparing (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid and structurally related compounds via enantioselective hydrogenation of prochiral olefins are disclosed. The methods employ novel chiral catalysts which include C1-symmetric bisphosphine ligands bound to transition metals.

The present invention provides matrix dosage form comprising varenicline or a pharmaceutically acceptable salt thereof at least one high molecular weight water soluble polymer; and at least one water-insoluble hydrophilic excipient.

A controlled release pharmaceutical composition of varenicline or a pharmaceutically acceptable salt thereof wherein said controlled release pharmaceutical composition comprises a coating and an antioxidant wherein said antioxidant is present in an amount equal to a weight percent greater than about 0.1 % but less than 5% of the coating layer.

The present invention provides matrix dosage form comprising varenicline or a pharmaceutically acceptable salt thereof at least one high molecular weight water soluble polymer; and at least one water-insoluble hydrophilic excipient.

Una combinación terapéutica que comprende voriconazol y un inhibidor de CYP2C19 antifúngico en la que el voriconazol está presente en una cantidad de 5 mg a 600 mg y el inhibidor de CYP2C19 antifúngico está presente en una cantidad de 5 mg a 500 mg y en la que el inhibidor de CYP2C19 antifúngico es fluconazol.

The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy particularly in the treatment of pain particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred AChE inhibitors are donepezil (Aricept®) tacrine (Cognex®) rivastigmine (Exelon®) physostgmine (Synapton®) galantamine (Reminyl) metrifonate (Promem) neostigmine (Prostigmin) and icopezil.

A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.

Use of (SS)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain nociceptive pain cancer pain back pain inflammatory pain musculo-skeletal disorders visceral pain pain from strains/sprains post-operative pain posttraumatic pain burns renal colic acute pain central nervous system trauma head pain and orofacial pain is disclosed. Use of (SS)-reboxetine or a pharmaceutically accep...